跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AT-367
首页
药物
AT-367
AT-367
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
NRP1-SPECIFIC ANTISENSE OLIGONUCLEOTIDES AND THEIR USE IN PREVENTING AND/OR TREATING DISEASES
EP 4698649 A1
申请人: SECARNA PHARMACEUTICALS GMBH & CO KG
优先权: 2023
CN
EP
WO
3 件公开
ENGINEERED NUCLEASES AND COMPOSITIONS AND METHODS THEREOF
EP 4788806 A1
申请人: ACRIGEN BIOSCIENCES
优先权: 2023
CN
EP
WO
3 件公开
Isolated polynucleotides and polypeptides, and methods of using same for increasing yield of plants
US 10260073 B2
申请人: EVOGENE LTD
优先权: 2012
US
3 件公开
Protein-based assays for screening of the IgE-receptor interaction
US 8927695 B2
申请人: JARDETZKY THEODORE S
优先权: 2011
US
2 件公开
Human Coagulation Factor VII Polypeptides
US 2009055942 A1
申请人: NOVO NORDISK HEALTHCARE AG
优先权: 2006
US
Anti-idiotypic antibodies neutralising the inhibiting activity of an inhibiting antibody directed against domain C1 of factor VIII
EP 2447284 A1
申请人: LFB BIOTECHNOLOGIES
优先权: 2007
EP
Modified family 6 glycosidases with altered substrate specificity
US 8263379 B2
申请人: TOMASHEK JOHN
优先权: 2009
US
1-methyl benzimidazole bridged di-8-hydroxyquinoline ligand and zinc complex and preparation method and application of ligand and complex
CN 109776500 A
申请人: GUANGZHOU INST TECH
优先权: 2019
CN
ENGINEERED NUCLEASES
WO 2025014798 A3
申请人: ACRIGEN BIOSCIENCES
优先权: 2023
WO
Method for non-integratedly reprogramming somatic cells into pluripotent stem cells
CN 120536372 A
申请人: SHENZHEN CELL INSPIRE BIOTECHNOLOGY CO LTD
优先权: 2025
CN
药物
反馈